Back to Search Start Over

EE49 Cost-Effectiveness of Relmacabtagene Autoleucel (ANTI-CD19 AUTOLOGOUS CAR-T CELL IMMUNOTHERAPY PRODUCT) Vs Salvage Chemotherapy for Chinese Relapsed or Refractory Large B-Cell Lymphoma Patients.

Authors :
Lin, Z
Zuo, C
Jiang, Y
Su, W
Yao, X
Man, Y
Wu, Q
Guo, Z
Su, F
Xuan, J
Source :
Value in Health. 2022 Suppl, Vol. 25 Issue 12, pS62-S63. 2p.
Publication Year :
2022

Subjects

Subjects :
*IMMUNOTHERAPY
*COST effectiveness
*LYMPHOMAS
*CANCER chemotherapy
*RITUXIMAB

Details

Language :
English
ISSN :
10983015
Volume :
25
Issue :
12
Database :
Academic Search Index
Journal :
Value in Health
Publication Type :
Academic Journal
Accession number :
160758667
Full Text :
https://doi.org/10.1016/j.jval.2022.09.302
Full Text Access
View/download PDF

Tools

Authors Abstract Subjects Details